Evidence map›Paper›PMID 40371031›Full record

ArticleIndian journal of microbiology2025

Ultrasensitive Impedimetric Biosensor for Ovarian Cancer Screening.

Shilpa Gundagatti, Sudha Srivastava

Abstract read
In one paragraph

Article in Indian journal of microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Shilpa GundagattiDepartment of Biotechnology, Jaypee Institute of Information Technology, Noida, India.
Sudha SrivastavaDepartment of Biotechnology, Jaypee Institute of Information Technology, Noida, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ovarian cancer is a significant health concern among the female vulnerable populations due to delayed diagnosis. Point-of-care devices that can be utilized for mass screening of the population may improve patient survival through early diagnosis. In this context, we report an ultrasensitive DNA-based nano-biosensor for the quantification of cancer biomarker miRNA-21 using a label-free sensing technique. Magnetite selenium (

Indexed as

Biosensors designGold nanoparticlesMagnetite selenium nanocompositesmiRNA-21Ovarian cancer detection

Identifiers

PMID40371031
PMCPMC12069207

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.